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The progress of translational research and enhancing
the prospects for personalized medicine require coordi-
nated efforts across a wide range of disciplines as well
as public-private partnerships of many kinds. Advances
in genomics and proteomics technologies are providing
more accurate data on more targets and more types of
targets than ever before. These include whole genome
sequence information; identification and quantification
of thousands of specific protein targets, including details
of a myriad of protein modifications; epigenetic modifi-
cations; and new frontiers that include micro RNAs and
protein and nucleic acid interactome complexities. Our
technological advances will continue unabated, as it is
unlikely that we have plumbed the depths of biological
complexity governing development and disease.
Clinical databases and the digitization of clinical infor-
mation have improved significantly along with the
advances in -omics technologies. Significant challenges
in defining and enforcing ontologies and encouraging
meta-data capture represent significant hurdles. The
Cancer Biomedical Informatics Grid (CaBIG) and other
tissue database projects have developed common dic-
tionaries of terms for cancer staging and defining diag-
nostic subclasses of cancer; such efforts are critical to
being able to query across databases. In this issue Surati
and colleagues at the University of Chicago outlined
their success in developing a Thoracic Oncology Data-
base that serves as a repository for well-annotated can-
cer specimens combined with clinical, genomic, and
proteomic data obtained from specific tumor tissue stu-
dies. Their goal was to make the database not just a
repository, but also a dynamic tool to drive data mining
and exploratory analysis for clinical and translational
research for thoracic oncology. In the article, the investi-
gators used non-small cell lung cancer samples from the
database combined with specific proteomic analyses of
these samples to examine functional relevance of protein
over- and under-expression. Clinical data for 1323
patients with non-small cell lung cancer was captured
and proteomic studies were performed on tissue sam-
ples from 105 patients. Initial biomarker studies identi-
fied receptor tyrosine kinase family members that were
over-expressed in tumor tissues. Since clinical data and
research data are present in a single database, investiga-
tors were able to powerfully address research questions
or plan studies that minimize duplication, maximize the
potential for valuable results and encourage additions to
the database by other investigators at the University of
Chicago and at other institutions. In fact the stated
goals of the study, as outlined in the accompanying
paper were to: (1) create a platform to house clinical,
genomic, and proteomic data from patients with thor-
acic malignancies; (2) tailor the platform to meet the
needs of clinical and basic science researchers; and (3)
utilize the platform in support of meaningful statistical
analysis to correlate laboratory and clinical information.
It is generally understood that well-annotated clinical
specimens are fundamental to advancing translational
medicine and clinical oncology care. For oncology, in
particular, the union of clinical and biologic data is at
the highest level of evolution. Standardization of biospe-
cimen collection and consent processes, processing and
annotation of biospecimens and prioritization of speci-
men use for translational research is a top priority for
the National Cancer Institute (NCI). To standardize and
disseminate best practices the NCI has developed the
Office of Biorepositories and Biospecimen Research
(OBBR) http://biospecimens.cancer.gov/default.asp. Sev-
eral other ongoing initiatives with NCI and the National
Human Genome Research Institute (NHGRI) are cur-
rently implementing standards as set forth by OBBR;
these initiatives include the Cancer Genome Atlas Pro-
ject (TCGA) http://tcga.cancer.gov/, the Cancer Genome
Anatomy Project (CGAP) http://cgap.nci.nih.gov/), the
International Cancer Genome Consortium (ICGC)
http://www.icgc.org/, the Repository of Molecular Brain
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Neoplasia Data (REMBRANDT) https://caintegrator.nci.
nih.gov/rembrandt/, the International HapMap Project
http://hapmap.ncbi.nlm.nih.gov/ and the 1000 Genomes
Project http://www.1000genomes.org/. In addition, other
NCI programs focused on therapeutic clinical trials for
cancer patients have also begun to implement OBBR’s
standards for their biobanking initiatives; e.g., the NCI’s
Cancer Therapy Evaluation Program (CTEP, http://ctep.
cancer.gov), the Early Detection Research Network
(EDRN, http://edrn.nci.nih.gov), and the Cooperative
Oncology Groups http://www.cancer.gov/cancertopics/
factsheet/. All of these resources serve to connect dis-
covery from biospecimens to the broader cancer
research community and building intelligent links
between individual institution and NCI and cooperative
group clinical trials is critical since this entire network
provides the largest collection of similarly treated indivi-
duals, many of whom do not have tissue acquisitions.
The Cancer Genome Atlas (TCGA) Project serves to
foster groundbreaking medical research using standar-
dized procedures for multi-site patient consent, biospe-
cimen collection, processing, banking and clinical
annotation (which also includes active patient follow-
up). The overarching goal of TCGA is to improve our
ability to diagnose, treat and prevent cancer via full
molecular characterization of more than 20 cancer
types. RNA and DNA from the same set of tumor and
matched normal samples are analyzed by multiple char-
acterization centers for copy number variation, chromo-
somal segment aberrations, loss of heterozygosity,
epigenetic alterations, gene and miRNA expression
changes as well as mutation by large-scale sequencing.
TCGA has an established, integrated network of clinical
sites, core resources, specialized genome characteriza-
tion and genome sequencing centers and incorporates
powerful bioinformatics and data analysis centers. The
Cancer Proteomics Centers http://proteomics.cancer.
gov/ will now be responsible for adding proteomics data
to this resource. As technologies are evolving rapidly,
the concept of “full” molecular characterization is a
moving target. However, TCGA has evolved and will
continue to evolve along with the technologies, with
more and more scientific papers and discoveries that
promise to ultimately lead to advances in cancer preven-
tion and treatment.
Going forward, the question as to how academic pro-
jects, such as that outlined by Surati and colleagues the
University of Chicago, may be linked and leveraged with
public projects is not yet answered. Agreements of stan-
dards and sharing of data and resources, especially those
that have been funded by public dollars, are critical to
progress. A role for cancer advocacy organizations can
be envisioned in this framework as they could play
advocate and/or provide seed funding for biobank
projects of specific interest to their donors, and this
seed funding could come with important strings
attached, namely that projects must be designed and
delivered for the benefit of the patients and the public.
If the advocacy groups can help build the resources, aca-
demic institutions may be best suited to properly
exploiting these with testable hypotheses. However, this
will require transparent and fair access policies for sam-
ples and data as well as cost recovery that maintains
these resources.
The recent identification of genetic mutations linked
to pathogenesis and clinical behavior in breast cancer,
colon cancer and glioblastoma and many other cancers
have advanced our knowledge in terms of clinical diag-
nosis and treatment tremendously. In fact, we can only
expect more powerful markers leading to robust patient
stratification as the quality of biobanks and their anno-
tations and the technologies used to acquire these data
improve. Some of the important next steps in oncology
management will require proteomics data to be available
along with the existing comprehensive genomic data as
technologies to analyze gene and protein expression
data in the context of gene and protein networks are
providing specific predictions for functional protein level
dysregulation. In addition, since proteomic expression
information is only modestly correlated with gene
expression data (e.g. r2 ~ 0.5-0.6) more careful examina-
tion where correlation is lacking may reveal the involve-
ment of novel pre- and posttranscriptional regulators
such as miRNAs and ubiquitination, respectively
In conclusion, momentum in building biobanking
resources with well-annotated clinical specimens is
growing, which can only further facilitate and acceler-
ate translational research discoveries. The NIH is
clearly concerned for the future of translation; the
development and maintenance of the Centers for
Translational Science will be critical to this future as
will the execution of plans for the National Center for
Advancing Translational Sciences. Individually, we
need to monitor strategic plans at our own institutions
to see that biospecimen resources do not become
museums but dynamic and evolving research
resources. This will require adequately vetted business
plans with careful analysis of scientific return on
investment. Developing regional networks through our
academic medical centers in collaboration with pri-
mary care health care networks is the next logical step.
Ultimately national and international level collabora-
tions might become the norm. In the meantime, the
importance of properly annotated biospecimen collec-
tion needs to be highlighted among the research com-
munity, patients and the general public. In the future,
patient oriented research could become more efficient
and more effective, leading to better treatment
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decisions, including when not to treat, and improved
clinical outcomes.
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